The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

The Invesco Health Care Fund underperformed its benchmark for the first quarter of 2025. Click here to read the full ...

Nutriband's AVERSA(TM) technology is advancing toward commercialization as the first abuse-deterrent transdermal fentanyl patch <li /> Re ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Stocks fell on Tuesday as Wall Street reacted to the latest round of tariff uncertainty and some mixed earnings reports.These ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Good day, ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected ...